179 related articles for article (PubMed ID: 33539850)
1. Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.
Stoll JR; Battle L; Moy A; Dusza SW; Park JH; Tallman MS; Taylor J; Markova A
J Am Acad Dermatol; 2022 Jan; 86(1):232-234. PubMed ID: 33539850
[TBL] [Abstract][Full Text] [Related]
2. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes.
Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F
Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100
[TBL] [Abstract][Full Text] [Related]
3. Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.
Howell G; Oliai C; Schiller G
Anticancer Res; 2018 Dec; 38(12):6927-6930. PubMed ID: 30504411
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Klingler F; Alsdorf WH; Ghandili S; Wolschke C; Brauneck F; Bokemeyer C; Fiedler W; Modemann F; Karagiannis P
Leuk Lymphoma; 2022 Nov; 63(11):2645-2651. PubMed ID: 35787724
[TBL] [Abstract][Full Text] [Related]
5. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia.
Benitez LL; Perissinotti AJ; Rausch CR; Klaus J; Clark SM; Filtz M; Ratermann K; Treptow C; Griffin S; Olson M; Crain M; Kadia T; Pettit K; Burke PW; Bixby DL; Marini BL
Leuk Lymphoma; 2021 Sep; 62(9):2184-2192. PubMed ID: 33830856
[TBL] [Abstract][Full Text] [Related]
6. Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia.
Kolitz JE; Strickland SA; Cortes JE; Hogge D; Lancet JE; Goldberg SL; Villa KF; Ryan RJ; Chiarella M; Louie AC; Ritchie EK; Stuart RK
Leuk Lymphoma; 2020 Mar; 61(3):631-640. PubMed ID: 31760835
[TBL] [Abstract][Full Text] [Related]
7. Recurrent and reversible bilateral palmar blue discoloration following administration of liposomal daunorubicin-cytarabine (Vyxeos®) for acute myeloid leukemia with myelodysplasia-related changes.
Triesel K; Chiang T; Seabury R; Miller C
J Oncol Pharm Pract; 2021 Sep; 27(6):1539-1541. PubMed ID: 33307969
[TBL] [Abstract][Full Text] [Related]
8. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
Maakaron JE; Mims AS
Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
[TBL] [Abstract][Full Text] [Related]
9. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
[TBL] [Abstract][Full Text] [Related]
10. CPX-351 for higher risk myelodysplastic syndrome: cytarabine and daunorubicin in disguise?
Muus P; de Witte T
Lancet Haematol; 2023 Jul; 10(7):e481-e482. PubMed ID: 37245521
[No Abstract] [Full Text] [Related]
11. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
[TBL] [Abstract][Full Text] [Related]
13. CPX-351 (vyxeos) in AML.
Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
[TBL] [Abstract][Full Text] [Related]
14. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
Asghari H; Lancet J
Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927
[TBL] [Abstract][Full Text] [Related]
15. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
[TBL] [Abstract][Full Text] [Related]
16. Recognizing the potential for copper-related toxicities from liposomal daunorubicin--cytarabine.
Newman MJ
J Oncol Pharm Pract; 2021 Apr; 27(3):776-777. PubMed ID: 33593136
[No Abstract] [Full Text] [Related]
17. Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia.
Kasner MT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):604-606. PubMed ID: 31851160
[No Abstract] [Full Text] [Related]
18. In brief: Two new drugs for AML.
Med Lett Drugs Ther; 2018 Mar; 60(1543):e56. PubMed ID: 29635267
[No Abstract] [Full Text] [Related]
19. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia.
Przespolewski A; Goldberg AD; Talati C; Fazal S; Vachhani P; Sanikommu SR; Thota S; Waksal J; Ball B; Famulare C; Stahl M; Baron J; Griffiths EA; Thompson JE; Sweet K; Wang ES
Blood; 2023 Mar; 141(12):1489-1493. PubMed ID: 36493344
[No Abstract] [Full Text] [Related]
[Next] [New Search]
